As I have said previously on a CDY thread Pharma I am a bit of a glass-half-full sort of person. For that reason, if I was tossing the coin, I would think it would have a better chance of coming down on the side of increased revenue outside of the China arrangement. That is, the projected “$33.3m” option I have referred to.
The main reason for the optimism is because the China agreement, as described in the announcements at least, seems to be very well defined in terms of minimum contracted volumes. There is though the possibility that although volumes are presumably unchanged there has been a reduction in the anticipated sale price or margin. One would however have thought that this would be well worked out before finalising the agreement.
poorinvestor
- Forums
- ASX - By Stock
- An Evaluation of CDY Going Forward
As I have said previously on a CDY thread Pharma I am a bit of a...
-
-
- There are more pages in this discussion • 96 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add AN1 (ASX) to my watchlist
(20min delay)
|
|||||
Last
0.8¢ |
Change
0.000(0.00%) |
Mkt cap ! $3.690M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Featured News
AN1 (ASX) Chart |
Day chart unavailable
The Watchlist
LGP
LITTLE GREEN PHARMA LTD
Paul Long, Chief Executive Officer
Paul Long
Chief Executive Officer
SPONSORED BY The Market Online